N-Cyclopropylmethylnoroxymorphone en es it fr

N-Cyclopropylmethylnoroxymorphone Brand names, N-Cyclopropylmethylnoroxymorphone Analogs

N-Cyclopropylmethylnoroxymorphone Brand Names Mixture

  • No information avaliable

N-Cyclopropylmethylnoroxymorphone Chemical_Formula


N-Cyclopropylmethylnoroxymorphone RX_link


N-Cyclopropylmethylnoroxymorphone fda sheet

N-Cyclopropylmethylnoroxymorphone FDA

N-Cyclopropylmethylnoroxymorphone msds (material safety sheet)

N-Cyclopropylmethylnoroxymorphone MSDS

N-Cyclopropylmethylnoroxymorphone Synthesis Reference

No information avaliable

N-Cyclopropylmethylnoroxymorphone Molecular Weight

341.401 g/mol

N-Cyclopropylmethylnoroxymorphone Melting Point

169-170 oC (274-276 oC for hydrochloride salt)

N-Cyclopropylmethylnoroxymorphone H2O Solubility

100 mg/mL (as hydrochloride salt)

N-Cyclopropylmethylnoroxymorphone State


N-Cyclopropylmethylnoroxymorphone LogP

1.692 (1.92 by expt)

N-Cyclopropylmethylnoroxymorphone Dosage Forms

Tablet (scored, film-coated, 50 mg)

N-Cyclopropylmethylnoroxymorphone Indication

For use in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids.

N-Cyclopropylmethylnoroxymorphone Pharmacology

Naltrexone, a pure opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. It markedly attenuates or completely blocks, reversibly, the subjective effects of intravenously administered opioids. When co-administered with morphine, on a chronic basis, naltrexone blocks the physical dependence to morphine, heroin and other opioids. In subjects physically dependent on opioids, naltrexone will precipitate withdrawal symptomatology.

N-Cyclopropylmethylnoroxymorphone Absorption

Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.

N-Cyclopropylmethylnoroxymorphone side effects and Toxicity

In the mouse, rat and guinea pig, the oral LD50s were 1,100-1,550 mg/kg; 1,450 mg/kg; and 1,490 mg/kg; respectively. High doses of naltrexone (generally ≥1,000 mg/kg) produce salivation, depression/reduced activity, tremors, and convulsions.

N-Cyclopropylmethylnoroxymorphone Patient Information

It is recommended that the prescribing physician relate the following information to patients being treated with REVIA:

You have been prescribed REVIA as part of the comprehensive treatment for your alcoholism or drug dependence. You should carry identification to alert medical personnel to the fact that you are taking REVIA. A REVIA medication card may be obtained from your physician and can be used for this purpose. Carrying the identification card should help to ensure that you can obtain adequate treatment in an emergency. If you require medical treatment, be sure to tell the treating physician that you are receiving REVIA therapy.

You should take REVIA as directed by your physician. If you attempt to self-administer heroin or any other opiate drug, in small doses while on REVIA, you will not perceive any effect. Most important, however, if you attempt to self-administer large doses of heroin or any other opioid while on REVIA, you may die or sustain serious injury, including coma.

REVIA is well-tolerated in the recommended doses, but may cause liver injury when taken in excess or in people who develop liver disease from other causes. If you develop abdominal pain lasting more than a few days, white bowel movements, dark urine, or yellowing of your eyes, you should stop taking REVIA immediately and see your doctor as soon as possible.

N-Cyclopropylmethylnoroxymorphone Organisms Affected

Humans and other mammals